AstraZeneca Plc disclosed the full results of its Phase 3 trial of baxdrostat, a drug for hypertension, on 30 August, confirming the therapy’s ability to reduce systolic blood pressure in patients with hard-to-control hypertension. In a presentation at the European Society of Cardiology Congress in Madrid, the company said that baxdrostat, a small molecule drug that inhibits aldosterone synthase, met all primary and secondary endpoints, delivering sustained blood pressure reductions.
At week 12 of the trial, the blood pressure reduction was 15.7 millimeters of mercury (mmHg) compared with a reduction of 9.8 mmHg for the placebo group. There were no unanticipated safety findings. Earlier, the company reported that baxdrostat was able to significantly lower aldosterone levels without affecting cortisol levels across a range of doses. This avoids the risk of adrenocortical insufficiency, a serious side effect.
Baxdrostat is being investigated as a potential monotherapy for hypertension and primary aldosteronism and in combination with dapagliflozin (Farxiga) for chronic kidney disease and hypertension and the prevention of heart failure in hypertensive patients. Sharon Barr, head of biopharmaceuticals R&D, said the company is looking forward to advancing its regulatory filings for the drug “in the months ahead.”
Copyright 2025 Evernow Publishing Ltd